Form 4: IQVIA Executive Granted Stock Appreciation Rights

Michael J. Fedock, SVP, FP&A at IQVIA Holdings Inc., was granted 18,634 Stock Appreciation Rights with a strike price of $192.67.

Summary

• Michael J. Fedock, Senior Vice President of Financial Planning & Analysis (SVP, FP&A) at IQVIA Holdings Inc., was granted Stock Appreciation Rights (SARs).
• The grant consists of 18,634 Stock Appreciation Rights.
• The exercise price for these Stock Appreciation Rights is $192.67.
• The transaction date for the grant was February 9, 2026.
• The Stock Appreciation Rights will vest in three annual installments, commencing on February 9, 2027.
• The expiration date for these Stock Appreciation Rights is February 9, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive incentive alignment and retention, which is generally favorable for corporate stability and long-term performance.

Positives

• The grant of Stock Appreciation Rights to a key executive like the SVP, FP&A, aligns management incentives with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention and sustained performance over time.

Negatives

• The Stock Appreciation Rights do not provide immediate cash or equity to the executive, as their value is contingent on future stock price appreciation above the exercise price.
• The value of the SARs is entirely dependent on the company's stock performing well above $192.67 per share in the future.

Risks

• The inherent risk is that if IQVIA Holdings Inc.'s stock price does not appreciate above the $192.67 exercise price, the Stock Appreciation Rights may expire worthless.

Future Outlook

The Stock Appreciation Rights are structured to vest over three annual installments beginning February 9, 2027, indicating a long-term incentive for the executive and a focus on sustained future performance.

Industry Context

StockSavvy.ai notes that granting Stock Appreciation Rights is a common executive compensation practice in the healthcare technology and life sciences industries, aiming to align executive incentives with long-term shareholder value creation without immediate dilution from direct stock grants.

Comparison to Industry Standards

• StockSavvy.ai observes that SAR grants are a standard component of executive compensation packages across large-cap pharmaceutical services and healthcare IT companies, comparable to practices at companies like Thermo Fisher Scientific or Laboratory Corporation of America Holdings.
• These types of equity incentives are widely used to retain talent and drive growth, with the specific grant size and strike price being typical for a senior vice president level within the industry.

Stakeholder Impact

• Shareholders: Potential positive impact through improved executive alignment with long-term stock performance, as the executive's compensation is tied to stock appreciation.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• The Stock Appreciation Rights will begin vesting in three annual installments starting February 9, 2027.
• The executive may exercise the vested SARs at any time before the expiration date of February 9, 2036, provided the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of executive compensation in the form of Stock Appreciation Rights. While it indicates continued alignment of management incentives with shareholder value, it does not present new information that would fundamentally alter the investment thesis for IQVIA Holdings Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

IQVIA Holdings Inc., IQV, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, Michael J. Fedock, SVP FP&A